Last Updated: August 15, 2026

Litigation Details for Esignature Software, LLC v. Adobe Inc. (Fed. Cir. 2023)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Esignature Software, LLC v. Adobe Inc.
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Esignature Software LLC v. Adobe Inc. (23-1711) | Litigation Summary, Claim Targets, and IP Exposure Analysis

Last updated: July 17, 2026

Esignature Software, LLC’s appeal in Esignature Software, LLC v. Adobe Inc., No. 23-1711 centers on Adobe’s e-signature and document workflow offerings and the validity/enforceability and infringement findings reflected in the case posture below the appellate level. Without the district court’s opinion, the asserted patent list, claim constructions, the tribunal’s infringement/validity rulings, and the specific issues briefed for appeal, a complete litigation summary and patent-focused risk analysis cannot be produced without omitting required hard data.

Key litigation identifiers required to analyze 23-1711 (not available in the prompt):

  • Asserted patent numbers (and assignees) at issue in the infringement suit
  • District court and docket (case number, venue, judge)
  • Final judgment date appealed to the circuit (and what was decided: infringement, validity, damages, injunction)
  • Claim construction outcomes used on appeal
  • PTAB status (inter partes review or ex parte reexamination tied to any asserted claims)
  • Appellate issue list (which questions the CAFC or relevant appellate panel accepted and how the appellant framed error)

Because the request is for a litigation summary and analysis for a specific docket number, and because the required record-level particulars are not provided, no accurate, complete, and citation-ready litigation summary can be delivered.

What patents were asserted in Esignature Software, LLC v. Adobe Inc. (23-1711)?

Featured snippet: The asserted patent(s) and claim(s) at issue in No. 23-1711 are not specified in the provided input, so a patent-by-patent litigation map cannot be stated.

Which Adobe products were accused (e-signature, Acrobat, Document Cloud)?

Featured snippet: The specific accused Adobe e-signature/document features tied to the asserted claims are not stated in the provided input.

What did the district court decide that led to appeal in 23-1711?

Featured snippet: The district court’s infringement and validity determinations, damages findings, and any injunction or declaratory relief were not provided, so the causal chain to the appeal cannot be summarized precisely.

What issues were presented on appeal?

Featured snippet: The appellate issues (infringement, claim construction, anticipation/obviousness, indefiniteness, written description, inequitable conduct, damages, or procedural rulings) are not provided.

When did Esignature Software v. Adobe (23-1711) reach key procedural milestones?

Featured snippet: A litigation timeline requires the lower-court judgment date, the notice of appeal date, briefing schedule, and any oral argument date. None are included in the prompt.

Timeline elements that are necessary for an execution-grade summary

  • Complaint filing date
  • Markman/claim construction decision date
  • Trial or dispositive motion decision dates
  • Final judgment and post-trial orders
  • Notice of appeal date
  • Appellate decision date

How strong was Esignature Software’s case on infringement for the asserted claims?

Featured snippet: Infringement strength depends on the asserted claim elements, Adobe’s product maps, and the lower court’s findings. These are not included in the prompt.

Claim construction impact on infringement analysis

Without the construed terms and mapping of each element, the infringement posture cannot be analyzed.

How did validity (anticipation/obviousness) play out in the lower court and on appeal?

Featured snippet: Patent validity analysis requires the asserted prior art set, the district court’s rationale, and the CAFC (or other appellate) review standards applied. None are provided.

Were any claims invalidated and were any upheld?

No patent validity outcomes are given.

What does the appellate decision change for Adobe’s e-signature patent exposure?

Featured snippet: The commercial exposure hinges on what claims survive and whether the ruling affects injunctive relief, damages, or licensing leverage. The decision outcome is not provided.

Does the appeal result create a licensing or settlement inflection point?

No information on settlement, stay, or remand instructions is included.

What generic or alternative risk models apply to Adobe competitors?

Featured snippet: Competitor risk requires: the surviving claim scope, the geographic reach (US only unless foreign equivalents), and whether alternative implementations avoid the patented elements. None of these inputs are present.

Key takeaways

No record-level information is provided to ground a litigation summary and infringement/validity analysis for Esignature Software, LLC v. Adobe Inc., No. 23-1711. A complete, accurate, and actionable litigation brief cannot be generated from the prompt alone.

FAQs

  1. What is the docket’s court and procedural posture for 23-1711? Not specified in the prompt.
  2. Which patents and claims does Esignature Software assert against Adobe in 23-1711? Not specified in the prompt.
  3. What did the lower court rule on infringement and validity before appeal? Not specified in the prompt.
  4. What products or Adobe features are accused in this appeal? Not specified in the prompt.
  5. What is the appellate outcome for No. 23-1711 (affirmed, reversed, remanded)? Not specified in the prompt.

References

No cited sources were provided in the prompt.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.